- The most cost-effective treatment option for refractory overactive bladder (OAB) is onabotulinumtoxinA (onabotA; Botox).
Why this matters
- Because of high health and economic burdens with OAB, cost-effectiveness is an important factor in treatment decisions, say the authors.
- Researchers developed a Markov model to compare the cost-effectiveness of treatment options with best supportive care over the course of 10 years.
- Treatments in addition to onabotA included implantable sacral nerve stimulation devices, percutaneous tibial nerve stimulation (PTNS), anticholinergic medications, and mirabegron (Myrbetriq).
- Funding: Allergan plc.
- Treatment with 100 U onabotA resulted in the most additional quality-adjusted life-years (QALYs; 7.179) and lowest estimated incremental cost-effectiveness ratio ($32,680/QALY).
- The next lowest cost-effectiveness ratio was for PTNS ($71,126/QALY).
- All other treatments yielded a cost-effectiveness ratio >$100,000/QALY.
- The analysis was based on costs in the United States.